$700 savings expire in:
- 00Days
- 00Hrs
- 00Mins
- 00Secs
Digital Partnering | September 16–17, 2025
8 Sept - Pre-Conference Investor Syndication Day - SGT / Singapore
Setting the stage by examining how Asia's biotech investment landscape is rapidly evolving, with syndication emerging as a critical tool to pool capital, mitigate risk, and foster cross-border collaboration. Expect macro-trends, data-driven insights, and a vision for the decade ahead.
- The evolving landscape of biotech investment in Asia
- How syndication is unlocking capital and de-risking investments
- The rise of cross-border funding collaborations
A practical deep-dive into the mechanics of biotech syndicates, featuring investors and founders who've navigated successful deals. Learn how to structure win-win partnerships, align diverse stakeholders, and avoid common pitfalls.
- Advantages of syndicate investing in biotech
- Best practices for structuring investor syndicates
- Lessons from successful syndicated funding rounds
Early-stage biotech faces unique funding challenges. This panel explores how angel networks, seed syndicates, and accelerators are bridging gaps—and how founders can leverage these models to attract capital and strategic support.
- The role of angel networks and seed syndicates in Asia
- Bridging the "valley of death" for early-stage biotech
- Case studies of syndicate-backed preclinical/Series A successes
- How early-stage syndicates attract follow-on capital
What separates high-performing syndicates from fragmented investor groups? Discuss governance, communication, and alignment strategies.
- What makes a successful syndicate?
- Aligning investor goals and risk appetites
As Asia’s biotech ecosystem globalizes, learn how to navigate regulatory, cultural, and operational hurdles in cross-border deals.
- Regulatory challenges and opportunities
- Structuring international co-investments
Explore how syndicates with domain expertise (e.g., pharma, diagnostics) can accelerate portfolio companies beyond financial support.
- Strategic investors’ role in R&D/commercialization
- What makes a successful partnership
Examining how blending different investor profiles (VCs, corporates, angels, family offices) creates stronger syndicates. Experts will share how diverse capital sources bring complementary value beyond funding, from technical expertise to global market access.
- How different investor types evaluate and add value to syndicates
- Case studies of successful diverse-capital collaborations
- Managing governance and decision-making in heterogeneous investor groups
A forward-looking debate on how emerging technologies, regulatory shifts, and global capital flows will reshape biotech syndication in Asia.
- Emerging biotech investment trends
- How AI, precision medicine, and novel therapeutics are shifting investor focus
- Predictions for the next decade of syndicate-backed biotech startups